At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CTNM Contineum Therapeutics, INC.
Post-Market Trading 03-24 16:28:27 EDT
7.76
+0.59
+8.23%
盘后7.76
+0.000.00%
16:14 EDT
| High7.88 | Low7.18 | Vol26.64K |
| Open7.24 | D1 Closing7.17 | Amplitude9.76% |
| Mkt Cap200.04M | Tradable Cap102.47M | Total Shares25.78M |
| T/O201.71K | T/O Rate0.20% | Tradable Shares13.21M |
| P/B1.01 | ROE-26.19% | EPS-2.14 |
| 52wk High22.00 | 52wk Low5.92 | P/E-3.62 |
| Dividend0.00 | Div.Yield0.00 | ROA-18.53% |
Contineum Therapeutics Appoints Diego Miralles to Board
TIPRANKS · 03-17
Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors
Business Wire · 03-17
Buy Rating for Contineum Therapeutics: Promising Pipeline and Market Opportunities
TIPRANKS · 03-13
JonesTrading Initiates Contineum Therapeutics at Buy With $23 Price Target
MT Newswires Live · 03-13
Contineum Therapeutics Inc : Jonestrading Initiates Coverage With Buy Rating; Price Target $23
THOMSON REUTERS · 03-13
Institutional investors in Contineum Therapeutics, Inc. (NASDAQ:CTNM) have had a wonderful week after share price increased 24%
Simply Wall St. · 03-13
Contineum price target lowered to $16 from $32 at Baird
TIPRANKS · 03-07
Contineum Therapeutics Inc: Cash Runway Projected Through 2027
THOMSON REUTERS · 03-06
Contineum Therapeutics Q4 2024 GAAP EPS $(0.56) Misses $(0.46) Estimate
Benzinga · 03-06
Press Release: Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones
Dow Jones · 03-06
BRIEF-Contineum Therapeutics Initiates Patient Dosing in Phase 1b Chronic Pain Trial of PIPE-791
Reuters · 03-04
Contineum Therapeutics Inc - Topline Data From Pipe-791 Phase 1B Trial Expected in Early 2026
THOMSON REUTERS · 03-04
Contineum Therapeutics Initiates Patient Dosing in Phase 1B Chronic Pain Trial of Pipe-791
THOMSON REUTERS · 03-04
Contineum Therapeutics to Present at the 2025 Leerink Partners Global Healthcare Conference
Business Wire · 03-03
Contineum Therapeutics Price Target Maintained With a $31.00/Share by RBC Capital
Dow Jones · 01-09
Contineum Therapeutics, Inc. Class A (CTNM) Receives a Buy from RBC Capital
TIPRANKS · 01-09
Contineum Completes Enrollment in Trial for Relapsing-Remitting Multiple Sclerosis Treatment
MT Newswires Live · 01-08
BRIEF-Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
Reuters · 01-08
Contineum Therapeutics Completes Enrollment in Phase 2 Pipe-307 Vista Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (Rrms)
THOMSON REUTERS · 01-08
BRIEF-Rapt Therapeutics Names Lori Lyons-Williams Chair Of The Board
Reuters · 01-06
Introduction
Company Name.
Contineum Therapeutics, INC.
Affiliated Markets:
NASDAQ
Listing Date:
2024-04-05
Main Business:
Issue price:
16.00
Invest in Global Markets with Tiger Brokers!Open App